Crohn’s Disease Trials

A phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's disease. 

A Phase 2a multicenter, randomized, platform study of targeted therapies for the treatment of adult subjects with moderate to severe crohn's disease involving risankizumab, ABBV-382, and litikizumab.    

A Phase 3b, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active Crohn's disease and obesity or overweight.

A Phase 3b, randomized, multicenter, open-label, active-controlled study to compare the efficacy and safety of guzelkumab versus risankizumab in the treatment of participants with moderately to severely active Crohn's disease. 

Phase 2b Randomized, double-blind, active-and placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of induction and maintenance combination therapy with guselkumab and golimumab in participants with moderately to severely active crohn's disease.